Please sign in to follow a disease.
Personalized sleep apnea plan aims to boost CPAP compliance
NCT ID NCT05246449
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a personalized treatment plan called VitalCare for people with obstructive sleep apnea who were starting CPAP therapy. The plan included remote monitoring and tailored follow-up to help patients use their CPAP machine more regularly. Researchers enrolled 113 participants and measured how many hours per night they used CPAP after three months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- personalized treatment plan (VitalCare) with remote monitoring
- What this could lead to
- If it works, this could help people with sleep apnea stick with their CPAP therapy, leading to better sleep and health.
- What could go wrong
- This is a small, early exploratory study. The personalized plan may not improve CPAP use for everyone, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
113 people
The number who actually took part.
- Started
-
Feb 2022
- Finished
-
Jun 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient diagnosed with Obstructive Sleep Apnoea Syndrome (OSAS) who is newly prescribed CPAP or APAP therapy at inclusion * Patient agreeing to the collection of data from their CPAP/APAP device via teletransmission * Patient equipped with a device compatible with the ResMed telemonitoring data platform * Patient who has signed the informed consent form for the study Exclusion Criteria: * Obese patient presenting hypoventilation * Patient at risk of other sleep disorders (e.g. severe insomnia) * Patient with physical, mental or cognitive inability to use all components of the remote medical monitoring project and individualised treatment plan, as determined by the investigator wishing to include the patient * Patient with severe COPD (FEV1 ≤ 50% predicted or modified Medical Research Council (mMRC) dyspnoea scale \> 2) * Patient with severe Chronic Heart Failure (NYHA stage III or IV) * Patient's refusal of CPAP/APAP treatment support * Previous CPAP/APAP treatment for Sleep Apnoea * Patient with ongoing Mandibular Advancement Device (MAD) or in the 12 previous months * Patient with no permanent place of residence * Patient participating in another drug or device study within the previous 30 days
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obstructive sleep apnoea syndrome (OSAS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Distrital de Santarém
Santarém, Portugal